Blis had previously signalled it had a strategy of investing for growth.
"Delivery on this strategy is expected to lead to a reduction in EBITDA for 2021 due to increased costs associated with building Blis' capacity for future commercialisation opportunities, including the launch of the skincare range," chief executive Brian Watson said.
"The board and management continue to closely monitor trading conditions while balancing longer term challenges and opportunities."
The company last month launched a Blis Probiotics store on Alibaba's Tmall Global marketplace tmall.com - China's largest cross-border marketplace - which it said would build brand awareness.
Trading revenue for the 9 months ending December 31, 2020 increased 10 per cent to $8.2m, compared with the previous year.
EBITDA increased 12 per cent to $1.5m over the period.
Blis said there was a sharp, Covid-driven lift in demand in the previous fourth quarter.
"In contrast this year we are expecting a more settled fourth quarter for 2021."
The company's net profit for the six months to September 30 came to $1.1m, up 41 per cent compared with the previous corresponding period.
Blis shares last traded at 8c, having gained 21.1 per cent over the past 12 months.